Show simple item record

dc.contributor.authorHoppe, Bradford S
dc.contributor.authorNichols, Romaine C
dc.contributor.authorFlampouri, Stella
dc.contributor.authorPankuch, Mark
dc.contributor.authorMorris, Christopher G
dc.contributor.authorPham, Dat C
dc.contributor.authorMohindra, Pranshu
dc.contributor.authorHartsell, William F
dc.contributor.authorMohammed, Nasiruddin
dc.contributor.authorChon, Brian H
dc.contributor.authorKestin, Larry L
dc.contributor.authorSimone, Charles B
dc.date.accessioned2022-05-31T13:20:26Z
dc.date.available2022-05-31T13:20:26Z
dc.date.issued2022-03-17
dc.identifier.urihttp://hdl.handle.net/10713/19023
dc.description.abstractPurpose: Hypofractionated radiation therapy has been safely implemented in the treatment of early-stage non-small cell lung cancer (NSCLC) but not locally advanced NSCLC owing to prohibitive toxicities with photon therapy. Proton therapy, however, may allow for safe delivery of hypofractionated radiation therapy. We sought to determine whether hypofractionated proton therapy with concurrent chemotherapy improves overall survival. Methods and Materials: The Proton Collaborative Group conducted a phase 1/2 single-arm nonrandomized prospective multicenter trial from 2013 through 2018. We received consent from 32 patients, of whom 28 were eligible for on-study treatment. Patients had stage II or III unresectable NSCLC (based on the 7th edition of the American Joint Committee on Cancer's staging manual) and received hypofractionated proton therapy at 2.5 to 4 Gy per fraction to a total 60 Gy with concurrent platin-based doublet chemotherapy. The primary outcome was 1-year overall survival comparable to the 62% reported for the Radiation Therapy Oncology Group 9410 trial. Results: The trial closed early owing to slow accrual, in part, from a competing trial, NRG 1308. Median patient age was 70 years (range, 50-86 years). Patients were predominantly male (n = 20), White (n = 23), and prior smokers (n = 27). Most had stage III NSCLC (n = 22), 50% of whom had adenocarcinoma. After a median follow-up of 31 months, the 1- and 3-year overall survival rates were 89% and 49%, respectively, and progression-free survival rates were 58% and 32%, respectively. No acute grade ≥3 esophagitis occurred. Only 14% developed a grade ≥3 radiation-related pulmonary toxic effect. Conclusions: Hypofractionated proton therapy delivered at 2.5 to 3.53 Gy per fraction to a total 60 Gy with concurrent chemotherapy provides promising survival, and additional examination through larger studies may be warranted. © 2022 The Authorsen_US
dc.description.urihttps://doi.org/10.1016/j.ijrobp.2022.03.005en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Radiation Oncology, Biology, Physicsen_US
dc.rightsCopyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.en_US
dc.titleChemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ijrobp.2022.03.005
dc.identifier.pmid35306151
dc.source.journaltitleInternational journal of radiation oncology, biology, physics
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record